Amgen Inc. (AMGN) RBC Capital Markets Global Healthcare Conference (Transcript)

Core Insights - Amgen Inc. has reported a strong start to 2025, with first-quarter revenues increasing by 9% and non-GAAP earnings per share rising by 24% year-over-year, driven by 14 products that delivered double-digit growth across various therapeutic areas [3]. Company Performance - The company experienced broad-based strength in its portfolio, particularly in general medicine, rare disease, inflammation, and oncology [3]. - The macro and policy environment remains fluid, especially concerning taxes and pricing, but Amgen emphasizes the need for more innovation in healthcare [4]. Product Highlights - Specific product highlights were anticipated to be discussed by the Senior Vice President of Global Marketing & Access, indicating a focus on key growth drivers within the portfolio [5].